Supplementary Figure S8 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Rohit Thummalapalli; Biagio Ricciuti; Chaitanya Bandlamudi; Daniel M. Muldoon; Hira Rizvi; Arielle Elkrief; Jia Luo; Joao V. Alessi; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Lingzhi Hong; Jianjun Zhang; John V. Heymach; Don L. Gibbons; Andrew J. Plodkowski; Vignesh Ravichandran; Mark T.A. Donoghue; Chad Vanderbilt; Marc Ladanyi; Charles M. Rudin; Mark G. Kris; Gregory J. Riely; Jamie E. Chaft; Matthew D. Hellmann; Natalie I. Vokes; Mark M. Awad; Adam J. Schoenfeld

doi:10.1158/1078-0432.27033022.v1

Abstract

Distribution of tumor mutational burden (TMB) z-scores among patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thummalapalli et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db64358752279a https://doi.org/10.1158/1078-0432.27033022.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S8 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Abstract

Discussion

Cite This Study

Supplementary Figure S8 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading